REGN Regeneron Pharmaceuticals
- Official Name: REGENERON PHARMACEUTICALS, INC.
- Headquarters: 777 Old Saw Mill River Road, TARRYTOWN, NY, 10591 US
- CEO: Leonard S. Schleifer
- Website: regeneron.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1R | Lost by 1.260 | (2.189) - (0.929) | ||
| 2025-07-16 | 1 | Won by 1.892 | (3.142) - (5.034) | ||
| 2025-07-23 | 2 | Lost by 13.919 | 1.078 - 14.997 | ||
| 2025-07-30 | 3 | Lost by 2.003 | (8.758) - (6.755) | ||
| 2025-08-06 | 4 | Won by 3.849 | 4.711 - 0.862 | ||
| 2025-08-07 | 1R | Won by 4.307 | 0.971 - (3.336) | ||
| 2025-08-13 | 5 | Lost by 10.321 | (2.433) - 7.888 | ||
| 2025-08-20 | 6 | Won by 2.904 | (0.516) - (3.420) | ||
| 2025-08-21 | 2R | Won by 1.491 | 1.128 - (0.363) | ||
| 2025-08-27 | 7 | Lost by 16.285 | (0.652) - 15.633 | ||
| 2025-09-03 | 8 | Lost by 3.526 | (4.016) - (0.490) | ||
| 2025-09-04 | 3R | Won by 2.238 | 0.599 - (1.639) | ||
| 2025-09-10 | 9 | Lost by 2.690 | (1.440) - 1.250 | ||
| 2025-09-11 | 4R | Lost by 0.029 | 2.236 - 2.265 | ||
| 2025-09-17 | 10 | Lost by 1.109 | 5.508 - 6.617 | ||
| 2025-09-24 | 11 | Lost by 1.129 | (1.341) - (0.212) | ||
| 2025-10-01 | 12 | Won by 12.154 | 3.961 - (8.193) | ||
| 2025-10-08 | 13 | Lost by 9.600 | (5.653) - 3.947 | ||
| 2025-10-15 | 14 | Won by 1.654 | 2.155 - 0.501 | ||
| 2025-10-22 | 15 | Won by 8.047 | 1.455 - (6.592) |
Latest News
Yahoo - 2026-10-17
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share
Regeneron's biggest growth driver still has plenty of fuel left in the tank.
Yahoo - 2026-10-16
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment Optional reduc...
Benzinga - 2026-10-16
Regeneron Pharma Says EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Alternative Dosing Schedule For Libtayo Across All Approved Indications
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatmentOptional reduct...
Yahoo - 2026-10-16
Did Earnings Beat Just Shift Regeneron Stock Investment Narrative?
Regeneron Pharmaceuticals reported Q2 revenue of US$4.29b, up 16.7% year on year, alongside positive 84 week Phase 3 OPTIMA data for Pasatru in adults...
Yahoo - 2026-10-15
Regeneron Pharmaceuticals (REGN) Reports 84 Week Phase III Efficacy For FOP Treatment
Regeneron Pharmaceuticals (NasdaqGS:REGN) reported new Phase III OPTIMA data showing Pasatru maintained efficacy out to 84 weeks in adults with FOP. T...
Yahoo - 2026-10-15
Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds
Regeneron Pharmaceuticals (REGN) shares have been in focus after the company reported quarterly revenue of US$4.29b, up 16.7% year on year. The result...
Yahoo - 2026-10-15
Regeneron (REGN) Stock Still Looks Below Fair Value On Fresh Trial Data
Regeneron Pharmaceuticals has seen its share price move around in recent years, and fresh trial results plus a major immunology alliance are back in f...
Yahoo - 2026-10-15
Sanofi (ENXTPA:SAN) Stock Looks Reasonable After Its Antibody Deal
Sanofi has seen its share price under pressure over recent years, and a key issue for investors now is how well that current price lines up with what ...
Benzinga - 2026-10-15
UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978
UBS analyst Trung Huynh upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $660 to $978.
Yahoo - 2026-10-15
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competi...
Yahoo - 2026-10-15
Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDA...
Yahoo - 2026-10-15
Here's Why You Should Add EYPT Stock to Your Portfolio Now
EyePoint's Duravyu faces a key LUCIA study data readout in late 2026, with results potentially paving the way for an NDA filing in 2027.
Yahoo - 2026-10-15
What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report
Regeneron Pharmaceuticals will release its third-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.
Yahoo - 2026-10-15
Here Are Thursday’s Top Wall Street Analyst Research Calls: AngloGold Ashanti, Bank of America, Cirrus Logic, Crocs, Diamondback Energy, Devon Energy, Netflix, PayPal, Spotify Technolgy , and More
Pre-Market Stock Futures: Futures are trading mixed, but the Nasdaq is down sharply Thursday morning as worries about AI overspending continue to emer...
Yahoo - 2026-10-14
What Could Send Regeneron Stock Higher?
Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying ...
ChartMill - 2026-10-14
Top S&P500 movers in Wednesday's session
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
SeekingAlpha - 2026-10-14
Longleaf Partners Global Fund Q3 2026 Portfolio Review
Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectation...
Yahoo - 2026-10-14
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales...
Yahoo - 2026-10-14
Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight
Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch.
SeekingAlpha - 2026-10-14
Longleaf Partners Fund Q3 2026 Portfolio Review
The market is regaining confidence in Avantorâs ability to grow organically and in Emmanuel Lignerâs turnaround plan.
Yahoo - 2026-10-13
Why A Biotech M&A Wave May Hit This Winter
Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them.
Yahoo - 2026-10-13
Regeneron reports 84-week Phase III data for Pasatru in adult FOP
The trial showed that Pasatru prevented new heterotopic ossification lesions, compared to nine in the placebo cohort.
Show more
Yahoo - 2026-10-12
Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month
ChartMill - 2026-10-12
Discover which S&P500 stocks are making waves on Monday.
Yahoo - 2026-10-12
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Benzinga - 2026-10-12
Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth
CNBC - 2026-10-12
Calls of the Day: Adobe, eBay and Regeneron
Yahoo - 2026-10-09
Is Vertex Stock Worth More Than Its Competitors?
Yahoo - 2026-10-08
What Is Going On With Regeneron Stock?
Yahoo - 2026-10-08
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
Benzinga - 2026-10-08
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810
Yahoo - 2026-10-08
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
Yahoo - 2026-10-07
Regeneron CEO on R&D, Data and Omics
Benzinga - 2026-10-07
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780
Benzinga - 2026-10-07
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779
Yahoo - 2026-10-06
Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)
SeekingAlpha - 2026-10-06
Genmab: Epkinly Shines In Phase 3 DLBCL Trial
Yahoo - 2026-10-06
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Benzinga - 2026-10-06
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950
Benzinga - 2026-10-05
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
SeekingAlpha - 2026-10-04
Regeneron: The Easy Money Has Been Made (Rating Downgrade)
Yahoo - 2026-10-02
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Yahoo - 2026-10-02
An $8 Billion Reason Why Regeneron Stock Is in Focus
Yahoo - 2026-10-02
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
Benzinga - 2026-10-02
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
Yahoo - 2026-10-02
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
Yahoo - 2026-10-02
Sanofi pays Regeneron up to $8B to expand immunology alliance
Yahoo - 2026-10-01
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
Yahoo - 2026-10-01
Why Regeneron (REGN) Stock Is Trading Lower Today
Yahoo - 2026-10-01
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
ChartMill - 2026-10-01
Which S&P500 stocks are moving on Thursday?
SeekingAlpha - 2026-10-01
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
Yahoo - 2026-10-01
Sanofi, Regeneron broaden alliance to find their next Dupixent
Yahoo - 2026-10-01
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Yahoo - 2026-10-01
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Yahoo - 2026-10-01
Pfizer’s eczema drug clears skin in mid-stage trial
Yahoo - 2026-10-01
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
Yahoo - 2026-10-01
Kodiak Sciences More Than Doubles on Eye Disease Trial Results
Benzinga - 2026-10-01
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930
Yahoo - 2026-10-01
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls
SeekingAlpha - 2026-10-01
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion
Benzinga - 2026-10-01
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Yahoo - 2026-10-01
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
Yahoo - 2026-10-01
Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights
Benzinga - 2026-10-01
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion
SeekingAlpha - 2026-10-01
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies - Slideshow
Benzinga - 2026-10-01
Regeneron Exec Says Co. Eligible To Receive $1B In Potential Milestone Payment With Start Of First Late-Stage Trial As Part Of Deal
Benzinga - 2026-10-01
Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $850 Price Target
Yahoo - 2026-10-01
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
Yahoo - 2026-10-01
Sanofi, Regeneron expand partnership in deal worth up to $8 billion
Yahoo - 2026-10-01
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Yahoo - 2026-10-01
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Benzinga - 2026-09-30
Sanofi Expands Regeneron Alliance With Four Long-Acting Antibodies, Paying $1B Upfront With Up To $7B In Milestones; Costs And Profits Shared Equally
Yahoo - 2026-09-30
Why Moderna (MRNA) Shares Are Falling Today
Yahoo - 2026-09-30
This Analyst Just Downgraded Moderna Stock. Here's Why.
Yahoo - 2026-09-30
MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum
Yahoo - 2026-09-29
REGN or ILMN: Which Is the Better Value Stock Right Now?
Yahoo - 2026-09-29
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Yahoo - 2026-09-29
BioFuture 2026 Convenes Industry Leaders in New York City to Explore the Trends Reshaping Biopharma and Healthcare
Yahoo - 2026-09-29
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
Yahoo - 2026-09-29
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Yahoo - 2026-09-29
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?
Yahoo - 2026-09-29
Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?
Benzinga - 2026-09-29
RBC Capital Reiterates Sector Perform on Regeneron Pharmaceuticals, Maintains $737 Price Target
SeekingAlpha - 2026-09-29
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Yahoo - 2026-09-29
New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs
Yahoo - 2026-09-28
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
Yahoo - 2026-09-28
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
Yahoo - 2026-09-28
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
Yahoo - 2026-09-28
Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 172%
Yahoo - 2026-09-28
Kodiak skyrockets on positive study data for 2 eye drugs
Yahoo - 2026-09-28
Kodiak’s stock rallies on Phase III wAMD success
Yahoo - 2026-09-28
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
Yahoo - 2026-09-28
Kodiak Sciences Stock Surges 156% After Eye-Disease Drugs Pass Key Trial
Yahoo - 2026-09-28
Why This Regeneron Eye Rival Just Catapulted More Than 120%
Yahoo - 2026-09-28
Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus
Yahoo - 2026-09-28
Kodiak Sciences Stock Pops 70% After Eye-Disease Drugs Pass Key Trial
Benzinga - 2026-09-28
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Benzinga - 2026-09-28
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Yahoo - 2026-09-25
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
Yahoo - 2026-09-24
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
Yahoo - 2026-09-24
Regeneron (REGN) Stock Still Looks Undervalued After A 40% Run
SeekingAlpha - 2026-09-23
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Yahoo - 2026-09-22
Is Regeneron Stock a Bargain Below $800?
Benzinga - 2026-09-22
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Yahoo - 2026-09-22
1 S&P 500 Stock Worth Your Attention and 2 We Ignore
Yahoo - 2026-09-20
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
Yahoo - 2026-09-18
In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
Yahoo - 2026-09-18
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
SeekingAlpha - 2026-09-18
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Yahoo - 2026-09-17
Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight
Yahoo - 2026-09-17
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia
Yahoo - 2026-09-16
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
Yahoo - 2026-09-16
Why This Biotech Stock Just Got a Rare Double Upgrade
Yahoo - 2026-09-15
Will Fianlimab-Libtayo Trial Misstatement Lawsuits Change Regeneron Pharmaceuticals' (REGN) Pipeline-Driven Narrative?
Yahoo - 2026-09-15
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo - 2026-09-15
Regeneron Pharmaceuticals (REGN) Could Be 5% Undervalued Following Trial Lawsuit News
SeekingAlpha - 2026-09-14
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Yahoo - 2026-09-14
Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
Yahoo - 2026-09-12
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
Benzinga - 2026-09-10
HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920
Yahoo - 2026-09-09
Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)
Yahoo - 2026-09-09
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
SeekingAlpha - 2026-09-09
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
ChartMill - 2026-09-09
Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount
Yahoo - 2026-09-08
Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock
Yahoo - 2026-09-08
Big Short Billionaire Goes Long: Michael Burry Avoids AI, Bets on Beaten own Stocks Instead
Yahoo - 2026-09-08
3 Reasons to Avoid REGN and 1 Stock to Buy Instead
Yahoo - 2026-09-07
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Yahoo - 2026-09-04
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
Yahoo - 2026-09-04
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
Yahoo - 2026-09-04
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Benzinga - 2026-09-02
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Yahoo - 2026-09-02
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB
SeekingAlpha - 2026-08-31
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
SeekingAlpha - 2026-08-31
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Yahoo - 2026-08-31
Non-Melanoma Skin Cancer Market: Focus on Disease Indication, Treatment Type, Country and Region, 2025-2035
Yahoo - 2026-08-28
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
Yahoo - 2026-08-27
Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?
Yahoo - 2026-08-27
Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?
Yahoo - 2026-08-27
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
SeekingAlpha - 2026-08-27
Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment
SeekingAlpha - 2026-08-27
GSK: Still One Of My Top Healthcare Picks
Yahoo - 2026-08-26
Veeva Systems Q2 Earnings Call Highlights
Yahoo - 2026-08-25
Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist Says
Yahoo - 2026-08-25
Veeva Vault CRM Selected by Regeneron
SeekingAlpha - 2026-08-25
Regeneron: Why I Still See Upside After The Rally
Benzinga - 2026-08-24
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
SeekingAlpha - 2026-08-24
Sanofi: Trump's Vaccine Policy Won't Break The Story
Yahoo - 2026-08-21
Oil Shipper Hits New High; Three Stocks Also Near Pivots
Yahoo - 2026-08-20
How Moderna’s Historic Short Squeeze Upended the AI Chip Trade
Yahoo - 2026-08-20
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug
SeekingAlpha - 2026-08-20
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
Yahoo - 2026-08-20
Regeneron to challenge Ipsen as FDA clears bone disease drug
Benzinga - 2026-08-20
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug
Benzinga - 2026-08-20
Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain Hemorrhage
Yahoo - 2026-08-20
Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy
Yahoo - 2026-08-19
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
Yahoo - 2026-08-19
Regeneron Announces Investor Conference Presentations
Yahoo - 2026-08-19
Is OPK Worth Buying as Valuation Meets Improving Business Trends?
Yahoo - 2026-08-19
Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?
Yahoo - 2026-08-19
Biotech Stocks Are Booming. What This Top Fund Is Buying Now.
Yahoo - 2026-08-19
HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation
SeekingAlpha - 2026-08-19
AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?
Yahoo - 2026-08-18
EyePoint’s Duravyu falls short to Eylea in Phase III trial
Yahoo - 2026-08-18
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
Benzinga - 2026-08-18
European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication
Yahoo - 2026-08-16
2 GLP-1 Stocks That Could Double Your Money by 2031
Yahoo - 2026-08-14
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
Yahoo - 2026-08-14
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
SeekingAlpha - 2026-08-14
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
Benzinga - 2026-08-14
If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
Yahoo - 2026-08-13
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Benzinga - 2026-08-12
Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'
Yahoo - 2026-08-11
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
SeekingAlpha - 2026-08-11
American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review
Yahoo - 2026-08-08
Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight
Yahoo - 2026-08-07
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Yahoo - 2026-08-06
CytomX Therapeutics Q2 Earnings Call Highlights
Yahoo - 2026-08-06
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
Yahoo - 2026-08-06
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ...
Benzinga - 2026-08-06
LibtayoReceives Health Canada Approval for Adjuvant Treatment Of High-Risk Cutaneous Squamous Cell Carcinoma
Yahoo - 2026-08-05
Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stock
SeekingAlpha - 2026-08-05
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
Yahoo - 2026-08-05
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
Yahoo - 2026-08-05
REGN or INCY: Which Is the Better Value Stock Right Now?
Yahoo - 2026-08-04
BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth
SeekingAlpha - 2026-08-04
OPKO Health: Mazdutide And MDX-2201 Could Change Everything
Benzinga - 2026-08-03
Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740
Benzinga - 2026-08-03
6 Health Care Stocks Whale Activity In Today’s Session
Yahoo - 2026-08-03
Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg
Benzinga - 2026-08-03
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030
Yahoo - 2026-07-31
S&P 500 ends with its first July decline since 2014. Here are the stocks that led the selloff.
Yahoo - 2026-07-31
Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?
Yahoo - 2026-07-31
AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling.
Benzinga - 2026-07-31
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $737
Yahoo - 2026-07-31
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.
Yahoo - 2026-07-31
Company News for July 31, 2026
Benzinga - 2026-07-31
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $758
Yahoo - 2026-07-31
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Yahoo - 2026-07-31
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Benzinga - 2026-07-31
Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $795
Benzinga - 2026-07-31
Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $750
Benzinga - 2026-07-31
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $772
Yahoo - 2026-07-31
Regeneron Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Yahoo - 2026-07-30
Regeneron (REGN) Q2 2026 Earnings Call Transcript
Yahoo - 2026-07-30
Regeneron (REGN) Stock Looks Cheap On Earnings Yet Mixed Elsewhere
Yahoo - 2026-07-30
Regeneron Pharmaceuticals Inc (REGN) (Q2 2026) Earnings Call Highlights: Record Dupixent Sales ...
Yahoo - 2026-07-30
Sector Update: Healthcare Stocks Decline Late Afternoon
Yahoo - 2026-07-30
Regeneron Pharmaceuticals Q2 Earnings Call Highlights
Yahoo - 2026-07-30
Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks
Yahoo - 2026-07-30
Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength
Yahoo - 2026-07-30
Why Regeneron (REGN) Is Up 6.7% After Mixed Q2 Results And New Telix Oncology Deal
SeekingAlpha - 2026-07-30
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call Transcript
SeekingAlpha - 2026-07-30
Regeneron Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
Yahoo - 2026-07-30
Regeneron Beats Second-Quarter Expectations as Dupixent Growth Fuels Strong Results
Yahoo - 2026-07-30
Regeneron (REGN) Q2 Earnings and Revenues Top Estimates
ChartMill - 2026-07-30
Regeneron Pharmaceuticals (NASDAQ:REGN) Surges After Crushing Q2 Estimates with Revenue and EPS Beat
Yahoo - 2026-07-30
Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales
Yahoo - 2026-07-30
Regeneron Reports Second Quarter 2026 Financial and Operating Results
Yahoo - 2026-07-30